Can Oral Probiotics Replace Chlorhexidine for Cavities?

Oral probiotics have a signal. They do not yet have a case for replacing chlorhexidine.

Oral probiotics can reduce Streptococcus mutans, a bacterium closely tied to tooth decay, compared with placebo or no treatment. That is a useful finding. It does not show that a probiotic prevents as many new cavities as chlorhexidine mouthwash, or that it can replace a clinician-recommended chlorhexidine regimen.

The difference matters because chlorhexidine is an antimicrobial treatment with a defined clinical role, while most probiotic trials measure saliva, plaque bacteria, pH, or microbiome composition over weeks. Those are surrogate outcomes. They can point in the right direction, but a lower bacterial count is not the same thing as fewer new lesions six or 12 months later.

The most interesting candidate is Streptococcus dentisani. Unlike chlorhexidine, which broadly suppresses microbes, this commensal bacterium may help make plaque less acidic. That biological argument is credible. The clinical proof remains incomplete.

The direct chlorhexidine comparison does not answer the replacement question

One identified randomized comparison tested a multi-strain probiotic against 0.2% chlorhexidine for S. mutans reduction in children and older adults. It ran for 14 days and used a superiority analysis, not a pre-specified equivalence or non-inferiority design. A finding of no statistically significant difference in that setting would not establish that the two treatments work equally well. Small, short studies often cannot distinguish a real difference from insufficient precision.

It also did not test S. dentisani or another probiotic with documented arginine deiminase activity. The formulation included several species, including Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, and Saccharomyces boulardii. You cannot borrow the biology of one strain and apply it to a different commercial blend like a lab coat in a relay race.

Two recent systematic reviews reach the same practical conclusion: probiotic-versus-chlorhexidine studies vary too much in strain, vehicle, duration, and outcomes to pool meaningfully, and no adequately powered equivalence-designed trial has shown that any probiotic matches chlorhexidine. Pérez-Leal et al.'s 2026 systematic review examined S. dentisani; Inchingolo et al.'s 2025 review assessed the broader probiotic-for-caries literature. Neither supports substitution.

Why S. dentisani attracts attention

Caries begins when plaque bacteria metabolize fermentable carbohydrates and lower local pH. Enamel starts to dissolve at roughly pH 5.5. S. dentisani has an arginine deiminase pathway that converts arginine to citrulline, then ornithine and ammonia. Ammonia can raise plaque pH, potentially moving the environment away from that dissolution threshold.

The organism also produces bacteriocins that antagonize S. mutans. The Pérez-Leal review, which included 14 clinical studies and more than 1,800 cumulative participants, reports early signals of more favorable salivary pH and microbiota changes. It also describes in-vitro antagonism against Candida, which may matter because oral Candida colonization is associated with higher caries prevalence in children.

Those mechanisms make sense. They do not prove a patient benefit. The same review found no clinical trial in which S. dentisani used caries incidence as its primary endpoint. Its human evidence therefore remains focused on pH and microbial measures, not on whether people developed fewer cavities.

What the broader probiotic evidence actually shows

The population-level finding is more modest and more solid: across strains, oral probiotics tend to reduce cariogenic bacteria versus placebo or control. A 2024 meta-analysis by Mayta-Tovalino et al. restricted to randomized trials in children and adolescents found statistically significant reductions in cariogenic bacteria with probiotics versus control. It did not pool comparisons against chlorhexidine, fluoride, or xylitol.

A double-blind, placebo-controlled trial provides a cleaner single-strain example. In Teanpaisan et al.'s 2024 study, 121 low-caries-risk adults used L. rhamnosus SD11 for four weeks. Compared with placebo, the probiotic group had significantly lower S. mutans and greater beneficial Firmicutes diversity at weeks 4 and 8 (p<0.05 at both time points). The eight-week finding suggests an effect outlasted active use, but the study did not include chlorhexidine and did not measure new cavities.

Riskier clinical settings do not erase that limitation. A 2023 systematic review and meta-analysis in orthodontic patients found oral-health benefits that included reductions in cariogenic bacteria. Braces create plaque-retention sites, so that population has a different risk profile from low-caries-risk adults. The endpoint still was largely microbial rather than incident caries.

Formulation is not a footnote

"Probiotic" is a category, not a treatment. Effects depend on the exact strain, dose, delivery vehicle, and exposure time. The broad 2025 review notes that some included studies associated L. acidophilus with caries progression rather than prevention. That does not mean every product containing the species causes cavities. It does mean that positive results from one strain cannot validate a multi-strain blend that contains another.

Short trials add another complication. Most studies lasted four to 12 weeks; a two-week intervention is poorly suited to test durable colonization or a sustained ecological change. A 2022 critical review of randomized trials documented wide variation in probiotic vehicles, oral outcomes, and study designs. This heterogeneity explains why the field has not produced a reliable pooled estimate against active comparators.

Nonviable approaches may eventually avoid some colonization and stability problems. A 2025 systematic review of postbiotics found inhibitory effects on S. mutans growth, biofilm formation, and virulence-related activity, but it included 18 in-vitro studies and only three randomized trials. That is an early evidence base, not a license to treat heat-killed bacteria as proven cavity prevention.

The more plausible role is alongside standard care

An adjunct strategy fits the evidence better than a replacement strategy. In a 2023 randomized trial by Pørksen et al., children received arginine plus probiotics as an add-on to 1,450 ppm fluoride toothpaste for caries prevention and control. Arginine supplies substrate for alkali-generating pathways in commensal oral bacteria, conceptually similar to the mechanism proposed for S. dentisani. The design asks whether microbial support can complement fluoride; it does not test whether probiotics can displace established care.

There is one encouraging exception to the field's reliance on surrogates. A 2025 double-blind, placebo-controlled trial enrolled 73 preschool children with at least one active carious lesion. It tested tablets containing inactivated Ligilactobacillus salivarius CECT 5317 plus cranberry extract for three months and assessed caries using ICDAS II at baseline and nine months. The study shows that a nonviable microbial formulation can be tested against a real clinical endpoint. Because it combines a paraprobiotic with cranberry, however, it cannot establish the independent effect of either component or answer the chlorhexidine question.

Verdict: An oral probiotic may be a reasonable adjunct to brushing with fluoride toothpaste and to individualized dental care. Do not replace prescribed chlorhexidine with a probiotic based on current evidence. L. rhamnosus SD11 has placebo-controlled evidence for short-term microbial effects; S. dentisani has the most coherent pH-based rationale. Neither has met the standard for a chlorhexidine substitute.